SEPN

Septerna Inc

Add to Watchlist

Advanced Chart

6.930

-0.070(-1.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

7.220

Open

7.010

VWAP

7.01

Vol

179.76K

Mkt Cap

307.99M

Low

6.850

Amount

1.26M

EV/EBITDA(TTM)

Total Shares

44.44M

-39.83M

EV/OCF(TTM)

P/S(TTM)

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. It is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

3 Analyst Rating

174.17% Upside

Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is 19.00 USD with a low forecast of 11.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

174.17% Upside

Current: 6.930

Low

11.00

Averages

19.00

High

27.00

174.17% Upside

Current: 6.930

Low

11.00

Averages

19.00

High

27.00

Wells Fargo

Derek Archila

Hold

Maintains

$14 → $11

2025-03-28

Reason

Wells Fargo

Derek Archila

Price Target

$14 → $11

2025-03-28

Maintains

Hold

Reason

Wells Fargo lowered the firm's price target on Septerna to $11 from $14 and keeps an Equal Weight rating on the shares. Following the discontinuation of their former oral PTH1R agonist, SEP-786, management aims to identify a new oral PTH1R agent by year-end 2025. With that lack of clinical catalysts in the next 12-18 months, the firm remains on the sidelines. That said, Wells believes progress and candidate selection for Septerna's next-gen PTH program is an important near-term milestone.

Wells Fargo

Derek Archila

Buy

Hold

Downgrades

$43 → $14

2025-02-18

Reason

Wells Fargo

Derek Archila

Price Target

$43 → $14

2025-02-18

Downgrades

Buy

Hold

Reason

Cantor Fitzgerald

Josh Schimmer

Buy

Reiterates

$50

2025-02-11

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$50

2025-02-11

Reiterates

Buy

Reason

TD Cowen

Yaron Werber

Strong Buy

Initiates

n/a

2024-11-19

Reason

TD Cowen

Yaron Werber

Price Target

n/a

2024-11-19

Initiates

Strong Buy

Reason

TD Cowen initiated coverage of Septerna with a Buy rating and no price target. The company is applying its Native Complex platform to build a pipeline of oral small molecule G protein-coupled receptor drugs, the analyst tells investors in a research note. The firm sees "significant potential for stock appreciation" based on Septerna's validated targets in sizable markets.

JP Morgan

Eric Joseph

Buy

Initiates

$38

2024-11-19

Reason

JP Morgan

Eric Joseph

Price Target

$38

2024-11-19

Initiates

Buy

Reason

JPMorgan analyst Eric Joseph initiated coverage of Septerna with an Overweight rating and $38 price target. Septerna represents a differentiated offering within broader biopharma, bringing predictive high-throughput screening and SAR optimization to the arena of G protein-coupled receptor targets, the analyst tells investors in a research note. The firm sees the company "executing a highly attractive pipeline strategy," focused on validated targets in large established indications where an oral option offers a clear benefit to patients.

Wells Fargo

Derek Archila

Buy

Initiates

$43

2024-11-19

Reason

Wells Fargo

Derek Archila

Price Target

$43

2024-11-19

Initiates

Buy

Reason

Wells Fargo analyst Derek Archila initiated coverage of Septerna with an Overweight rating and $43 price target. The firm believes there is upside for the shares on SEP-786's Phase 1 results, which it says "will be de-risking given the precedent datasets" for other parathyroid hormone programs. At this point, Wells views Septerna's SEP-631 "as a free call option." It likes the the company's Native Complex platform approach and thinks SEP-786's preclinical data should translate well to the clinic.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Septerna Inc (SEPN.O) is -3.73, compared to its 5-year average forward P/E of -5.25. For a more detailed relative valuation and DCF analysis to assess Septerna Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.25

Current PE

-3.73

Overvalued PE

-2.26

Undervalued PE

-8.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.66

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.31

Undervalued EV/EBITDA

-7.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

320.54

Current PS

820.28

Overvalued PS

720.79

Undervalued PS

-79.72

Financials

Annual

Quarterly

FY2024Q4

YoY :

+79.66%

212.00K

Total Revenue

FY2024Q4

YoY :

+85.74%

-24.72M

Operating Profit

FY2024Q4

YoY :

-159.23%

-20.67M

Net Income after Tax

FY2024Q4

YoY :

-185.14%

-0.63

EPS - Diluted

FY2024Q4

YoY :

+114.93%

-21.57M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-76.51%

-6.47K

FCF Margin - %

FY2024Q4

YoY :

-132.97%

-9.75K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

608.2K

USD

Months

3-6

439.3K

USD

Months

6-9

86.8M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

16.7M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

608.2K

USD

Months

3-6

439.3K

USD

Months

6-9

86.8M

USD

Months

0-12

0.0

USD

Months

SEPN News & Events

Events Timeline

2025-03-27 (ET)

2025-03-27

08:18:36

Septerna sees cash runway into early 2028

2025-03-27

08:18:13

Septerna reports Q4 EPS (64c), consensus (69c)

2025-01-06 (ET)

2025-01-06

06:04:27

Septerna appoints Labrucherie as Chief Financial Officer

News

7.0

03-17PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

9.5

03-14Benzinga

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

5.0

03-05Yahoo Finance

Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently

People Also Watch

BBW

Build-A-Bear Workshop Inc

HarborOne Bancorp Inc

Gambling.com Group Ltd

Verve Therapeutics Inc

DoubleDown Interactive Co Ltd

SBC Medical Group Holdings Inc

Midland States Bancorp Inc

Palmer Square Capital BDC Inc

12.710

USD

-0.31%

FAQ

What is Septerna Inc (SEPN) stock price today?

The current price of SEPN is 6.93 USD — it has decreased -1 % in the last trading day.

SEPN

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SEPN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Septerna Inc (SEPN) stock price today?

What is Septerna Inc (SEPN)'s business?

What is the price predicton of SEPN Stock?

What is Septerna Inc (SEPN)'s revenue for the last quarter?

What is Septerna Inc (SEPN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Septerna Inc (SEPN)'s fundamentals?

How many employees does Septerna Inc (SEPN). have?

What is Septerna Inc (SEPN) market cap?